[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platelet-rich-plasma-prp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platelet-rich-plasma-prp":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,86,121,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100643966","platelet-rich-plasma-versus-standard-care-for-episiotomy-wound-healing-in-postpartum-women-100643966",false,"NCT07669285","Platelet-Rich Plasma Versus Standard Care for Episiotomy Wound Healing in Postpartum Women","Efficacy of Autologous Platelet-Rich Plasma in Enhancing Episiotomy Wound Healing and Reducing Postpartum Perineal Pain: A Prospective Randomized Controlled Trial (PRP-EpiHeal)","PRP-EpiHeal","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Singular pregnancy, at term (≥ 37 weeks of gestation)\n* Vaginal delivery with episiotomy (midline or mediolateral)\n* Signed informed consent to participate in the study\n\nExclusion Criteria:\n\n* Known coagulation disorders or thrombocytopenia (\\\u003C 100,000\u002Fmm³)\n* Severe anemia (hemoglobin \\\u003C 7 g\u002FdL) at the time of delivery\n* Active systemic or local perineal infection at the time of delivery\n* Uncontrolled diabetes mellitus or other significant comorbidities affecting wound healing (e.g., autoimmune disease under immunosuppressive treatment) Third- or fourth-degree perineal laceration (extending to the anal sphincter or rectal mucosa) Refusal to participate or inability to provide informed consent",true,"FEMALE","18 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study looks at whether a treatment made from a patient's own blood, called platelet-rich plasma (PRP), can help heal the cut made during childbirth (episiotomy) better than standard care alone.\n\nPRP is prepared by drawing a small blood sample from the patient and spinning it in a centrifuge to concentrate the platelets, which contain natural healing factors. In this study, women who have an episiotomy during vaginal delivery will be randomly assigned to one of two groups: one group will receive a single injection of their own PRP at the wound site right after delivery, and the other group will receive the usual standard wound care. Neither group's care will otherwise differ.\n\nResearchers will follow each woman for 6 weeks after delivery, checking how well the wound is healing using a standard scoring tool (REEDA score), along with pain levels, any complications like infection or wound reopening, and how satisfied participants are with their recovery.\n\nThe goal is to find out whether this simple, low-risk treatment using a woman's own blood can speed up healing and reduce discomfort after childbirth.",[28,29,30,31],"Episiotomy","Platelet Rich Plasma (PRP)","Wound Healing","Obstetric",[33,34,35,36,37],"episiotomy","platelet rich plasma","wound healing","obstetric","postpartum period","NOT_YET_RECRUITING","2026-06-25",{"date":41,"type":42},"2026-06-30","ACTUAL",{"date":44,"type":22},"2026-06-21",{"date":46,"type":22},"2028-12-30",{"name":48,"class":49},"Saint Andrew Hospital Constanta","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":19,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":83,"locationsCount":85},"100640546","ultrasound-guided-platelet-rich-plasma-versus-local-anesthetic-injection-for-chronic-neuroma-pain-after-combat-related-amputation-100640546","NCT07624890","Ultrasound-Guided Platelet-Rich Plasma Versus Local Anesthetic Injection for Chronic Neuroma Pain After Combat-Related Amputation","Ultrasound-Guided Platelet-Rich Plasma Versus Local Anesthetic Injection for Chronic Neuroma Pain After Combat-Related Amputation: A Prospective Multicenter Controlled Study","PRP-NEUROMA","Inclusion Criteria:\n\n* Age ≥18 years\n* Combat-related limb amputation\n* Chronic neuroma pain lasting ≥3 months\n* Ultrasound-confirmed painful neuroma\n* Average neuroma pain intensity ≥4\u002F10 on the Numeric Rating Scale\n* Persistent pain interfering with rehabilitation, prosthesis use, or daily activities\n* Ability to undergo ultrasound-guided injection\n* Stable analgesic regimen for at least 14 days before enrollment\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Active infection at or near the injection site\n* Open wound preventing safe injection\n* Previous PRP injection for neuroma pain within 6 months\n* Previous neuroma surgery within 3 months\n* Severe coagulopathy or platelet disorder\n* Anticoagulant therapy contraindicating injection\n* Active malignancy\n* Severe uncontrolled systemic disease\n* Known allergy to local anesthetics\n* Inability to complete follow-up assessments","ALL","60 Years",{"count":62,"type":22},100,[25],"Patients with combat-related amputations frequently experience chronic neuroma pain that may interfere with rehabilitation, prosthesis use, mobility, sleep, and quality of life. Current treatment approaches often provide only temporary pain relief.\n\nPlatelet-rich plasma (PRP) has emerged as a potential regenerative treatment option because of its possible effects on tissue healing, neuroinflammation, and peripheral nerve irritation. However, its role in the treatment of chronic neuroma pain after amputation remains unclear.\n\nThis prospective multicenter controlled study aims to compare ultrasound-guided PRP injection around the neuroma with ultrasound-guided local anesthetic injection in patients with chronic neuroma pain after combat-related amputation.\n\nParticipants will undergo one of the two injection treatments and will be followed over time to evaluate changes in pain intensity, neuropathic pain symptoms, phantom limb pain, prosthesis tolerance, and functional outcomes.\n\nThe goal of the study is to evaluate the safety, feasibility, and potential clinical effectiveness of PRP injection for chronic neuroma pain following combat-related amputation.",[66,67,68,69],"Neuroma","Phantom Limb Pain After Amputation","Stump Pain","Platelet-rich Plasma (PRP)",[71,72,73,74,75,76],"Chronic Neuroma Pain","Residual Limb Pain","Combat-Related Amputation","Post-Amputation Pain Syndrome","Painful Stump Neuroma","Platelet-rich plasma","2026-05-30",{"date":79,"type":42},"2026-06-03",{"date":81,"type":22},"2026-12-15",{"date":81,"type":22},{"name":84,"class":49},"Ukrainian Society of Regional Anesthesia and Pain Therapy",2,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":98,"conditions":99,"keywords":105,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100627987","experimental-study-on-the-use-of-intrauterine-infusion-of-autologous-platelet-rich-plasma-prgf-iui-in-patients-with-recurrent-implantation-failure-andor-refractory-thin-endometrium-100627987","NCT07455773","Experimental Study on the Use of Intrauterine Infusion of Autologous Platelet-rich Plasma (PRGF-IUI) in Patients With Recurrent Implantation Failure and\u002For Refractory Thin Endometrium","PMA_PREPAIRE STUDY: Experimental Study on the Use of Intrauterine Infusion of Autologous Platelet-rich Plasma (PRGF-IUI) in Patients With Recurrent Implantation Failure and\u002For Refractory Thin Endometrium.","PMA_PREPAIRE","Inclusion Criteria:\n\n* Female patients aged 18 to 45 years\n* Body mass index (BMI) between 18 and 30 kg\u002Fm\n* Undergoing assisted reproductive technology (ART) cycle with hormone replacement therapy\n* Endometrial thickness \\\u003C 7 mm after at least 10 days of hormone replacement therapy\n* History of at least one failed embryo transfer\n* Normal hematologic and biochemical laboratory results\n* Ability to understand and sign written informed consent\n\nExclusion Criteria:\n\n* Endometrial hyperplasia or uterine malignancy\n* Active pelvic inflammatory disease or untreated sexually transmitted infection\n* Coagulation disorders or platelet abnormalities\n* Thrombocytopenia (\\\u003C100,000\u002Fmm³)\n* Chronic anticoagulant therapy\n* Active systemic infection or immunodeficiency\n* Contraindications to intrauterine procedures","45 Years",{"count":96,"type":22},80,[25],"Endometrial receptivity is a key determinant of success in assisted reproductive technology (ART). A significant proportion of patients experience repeated implantation failure despite euploid embryos and adequate laboratory conditions. Thin endometrium, often defined as ultrasound-measured thickness \\\u003C7 mm at embryo transfer, is frequently refractory to estrogen therapy and associated with low implantation and clinical pregnancy rates.\n\nPlatelet-Rich Plasma (PRP), obtained from autologous blood by double centrifugation, is rich in growth factors capable of stimulating cell proliferation, angiogenesis, and tissue regeneration, suggesting potential benefits for endometrial function. Preliminary studies indicate improved endometrial thickness and reproductive outcomes following intrauterine PRP infusion, but standardized protocols and systematic data are lacking.\n\nThe PMA\\_PREPAIRE study is a prospective, single-center, controlled, non-randomized interventional clinical trial conducted at the Reproductive Medicine Center of Cardinal Massaia Hospital, Asti. The study aims to evaluate the efficacy and safety of intrauterine infusion of autologous platelet-rich plasma (PRP), in association with hormone replacement therapy (HRT), in improving endometrial receptivity and reproductive outcomes in women with thin or refractory endometrium. The study includes a prospective control group treated with standard HRT alone.\n\nEligible women will be treated with standard clinical care, with PRP infusion offered to those with insufficient response to HRT. Inclusion criteria include age 18-45, BMI 18-30 kg\u002Fm², history of ≥1 failed embryo transfer, EMT \\\u003C5 mm after ≥10 days of HRT, and normal routine lab tests. Exclusion criteria include endometrial disease, recent gynecological infection, and systemic conditions such as thrombocytopenia or coagulopathies.\n\nProcedures include standard HRT from cycle days 1-2, serial ultrasound monitoring of endometrial thickness from days 6-8, intrauterine PRP infusion if EMT ≤7 mm (up to three infusions per cycle), embryo transfer once EMT ≥7 mm, and follow-up through pregnancy testing and confirmatory ultrasound.\n\nCollected data will be analyzed using descriptive statistics, paired and unpaired comparative analyses, and multivariate logistic regression models to evaluate predictors of treatment response and reproductive outcomes (significance level p \\\u003C 0.05).\n\nA sample size of 34 patients per group was estimated to detect a 1.5 mm difference in endometrial thickness (EMT) with 90% statistical power. Considering an anticipated dropout rate of 15%, a total of 40 patients per group will be enrolled.\n\nThe study includes:\n\nan intervention group consisting of 40 patients treated with HRT plus intrauterine PRP infusion; a prospective control group consisting of 40 patients with refractory thin endometrium treated with standard HRT alone, without PRP.",[100,101,102,103,69,104],"Recurrent Implantation Failure","Endometrial Receptivity Disorders","Embryo Implantation","Platelet-Rich Plasma","Infertility, Female",[106,107,108,76,109,110],"Endometrial receptivity","Recurrent implantation failure","Assisted reproductive technology","Intrauterine infusion","Autologous biological therapy","2026-05-12",{"date":113,"type":42},"2026-05-14",{"date":115,"type":22},"2026-05-01",{"date":117,"type":22},"2027-12",{"name":119,"class":120},"Azienda Sanitaria Locale di Asti","OTHER_GOV",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":59,"minAge":19,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":131,"conditions":132,"keywords":135,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":50},"100607543","comparative-real-world-study-on-ablative-fractional-co-laser-vs-prp-with-microneedling-for-acne-scar-treatment-100607543","NCT07189923","Comparative Real-world Study on Ablative Fractional CO₂ Laser vs PRP With Microneedling for Acne Scar Treatment.","Efficacy and Safety of Ablative Fractional CO2 Laser and Platelet-rich Plasma (PRP) With Microneedling for Treatment of Acne Scars: a Real-world Comparative Study","Inclusion Criteria:\n\n* Adult patients (age \\>18 years)\n* Both male and female sex\n* Patients with grade 2 to grade 4 acne scars, classified on the basis of Goodman's Qualitative classification.\n* Patient with equal Goodman's Qualitative scores on both halves of the face.\n* No active acne lesions.\n* Patients with atrophic scars only.\n\nExclusion Criteria:\n\n* Positive history of keloidal tendency.\n* Positive history of bleeding or platelet disorder.\n* Positive history of major surgery in past 6 months.\n* Presence of any acute infection on face like, herpes, folliculitis.\n* Patients of HIV, HBsAg, or any chronic illness.\n* Pregnancy",{"count":129,"type":22},116,[25],"Road traffic accidents (RTAs) remain a major public health concern worldwide and in Bangladesh, contributing significantly to injury, disability, and premature death. In resource limited settings like Bangladesh, it is crucial to understand the factors that influence survival following an RTA in order to develop effective prevention strategies and improve patient outcomes. Therefore, this study aims to determine the 30 day survival rate and identify predictors of survival among adult RTA victims treated at a tertiary care hospital in Bangladesh. The observational study will be carried out at Emergency and casualty department of Dhaka Medical College Hospital (DMCH) between October 2025 and March 2026. A total of 204 adults (≥18 years) presenting to the hospital's Casualty Department with RTA related injuries will be included. Informed written consent will be obtained from each patient or their legal guardian prior to enrollment. Data will be collected through structured face to face interviews, review of hospital records, and follow up on the 30th day of accident. The follow-up will be conducted either in person or by telephone. Variables will include patient demographics, accident circumstances, admission characteristics, injury pattern and severity, pre-hospital care, clinical condition at admission, hospital management provided, and treatment outcome. All data will be analyzed using SPSS version 25.0. Kaplan-Meier analysis will estimate survival probabilities, while Cox proportional hazards regression will be used to identify independent predictors of mortality. The findings of this study are expected to generate context-specific, evidence-based insights for strengthening trauma care protocols, gap related to emergency handling of the RTA patients, enhancing pre-hospital emergency services, and informing policy decisions aimed at reducing preventable RTA-related mortality and morbidity in Bangladesh.",[133,134,69],"Acne Scars","Ablative Fractional CO₂ Laser Therapy",[133,136,137,138,139,140,141,142],"Ablative fractional CO₂ laser therapy","Platelet-rich plasma (PRP)","Microneedling","Efficacy","Safety","Bangladesh","Goodman and Baron scale","2025-12-02",{"date":145,"type":42},"2025-12-03",{"date":147,"type":22},"2025-12-01",{"date":149,"type":22},"2026-11-30",{"name":151,"class":49},"Dr. Sirajul Islam Medical College",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":59,"minAge":19,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":165,"conditions":166,"keywords":170,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100593378","phase-2-use-of-prp-in-open-surgery-for-type-a-aortic-dissection-100593378","NCT07005661","Use of PRP in Open Surgery for Type A Aortic Dissection","Multicenter, Prospective, Randomized Controlled Trial of Autologous Platelet Rich Plasma (PRP) Use in Open Surgery for Type A Aortic Dissection","Inclusion Criteria:\n\n1. Undergoing open surgery for type A aortic dissection (TAAD);\n2. Body weight between 60-100 kg; hemoglobin (Hb) \\> 120 g\u002FL; platelet count (PLT) ≥ 120 × 10⁹\u002FL;\n3. Able to understand the purpose of the study, voluntarily participate, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Requires mechanical ventilation before surgery;\n2. Age under 18 or over 70 years;\n3. Use of anticoagulant or antiplatelet drugs within 7 days before surgery;\n4. Cardiogenic shock, cardiac arrest, severe hypotension (requiring two or more vasopressors), or mechanical circulatory support within 24 hours before surgery;\n5. Renal failure requiring dialysis;\n6. Severe coagulopathy or active bleeding tendency;\n7. Known history of heparin-induced thrombocytopenia (HIT);\n8. Severe psychiatric illness or other conditions affecting study reliability;\n9. Any condition deemed unsuitable by the investigator.","70 Years",{"count":161,"type":22},250,[163,164],"PHASE2","PHASE3","The goal of this clinical trial is to determine if autologous platelet rich plasma (PRP) can reduce the need for blood transfusions in patients undergoing open surgery for Type A aortic dissection. It will also evaluate the potential organ-protective effects of autologous PRP. The main questions it aims to answer are:\n\n1. Does PRP reduce the amount of allogeneic red blood cell transfusions for participants?\n2. Does PRP administration provide protective effects on organs (heart, liver, lungs, kidneys, brain) in participants?\n\nResearchers will compare the administration of autologous PRP with no PRP infusion to assess whether PRP can reduce blood transfusions and provide organ-protective effects in patients undergoing open surgery for Type A aortic dissection.\n\nParticipants will:\n\n1. Receive autologous PRP infusion during surgery\n2. Undergo multiple checkups and tests before and after surgery\n3. Be recorded for allogeneic red blood cell usage within 24 hours perioperatively and all allogeneic blood products usage during the entire hospitalization\n4. Be assessed for organ function (heart, liver, lungs, kidneys, brain) and symptom-related outcomes through clinical evaluations",[167,168,29,169],"Aortic Dissection Type A","Transfusions","Organ Protection",[171,172,34],"aortic dissection","transfusions","2025-06-03",{"date":175,"type":42},"2025-06-05",{"date":177,"type":22},"2025-06-30",{"date":179,"type":22},"2028-10-31",{"name":181,"class":49},"Beijing Anzhen Hospital"]